Endomimetics

Endomimetics is a private, pre-revenue biotech company pioneering a nanotechnology platform called Bionanomatrix™. This platform utilizes peptide-based coatings and gels that release nitric oxide and other agents to improve healing, reduce complications like infection and thrombosis, and enhance the integration and longevity of medical implants. With applications spanning cardiovascular, orthopedic, and dental fields, the company aims to address significant unmet needs in surgical and implant outcomes through strategic partnerships and future commercialization.

Bionanomatrix™: A customizable, peptide-based nanotechnology platform that can be applied as a coating or gel. It releases nitric oxide (and optionally antibiotics) to promote endothelialization, reduce inflammation, inhibit thrombosis, prevent infection, and improve tissue integration for medical implants and surgical sites.

Endomimetics competes with other companies developing bioactive coatings for medical devices, such as those using heparin, sirolimus, or other anti-proliferative drugs. Its differentiation lies in the multifunctional nitric oxide release mechanism, which addresses inflammation, thrombosis, and healing simultaneously. It also faces competition from companies developing adjunctive surgical gels and sealants.